溶瘤病毒
表观遗传学
生物
重编程
溶瘤腺病毒
癌症
溶癌病毒
免疫检查点
免疫疗法
免疫系统
癌症研究
封锁
免疫学
计算生物学
免疫调节
抗原
染色质
生物信息学
联合疗法
临床试验
癌症免疫疗法
治疗方式
病毒疗法
临床实习
表观遗传疗法
染色质重塑
后生
治疗方式
抗药性
作者
Saira Zulfiqar,Xiaoyan Wang,Baofu Chen,Yigang Wang
出处
期刊:Epigenomics
[Future Medicine]
日期:2026-09-29
卷期号:18 (10): 1249-1262
标识
DOI:10.1080/17501911.2026.2739787
摘要
Therapeutic resistance remains a defining limitation in the management of advanced solid tumors, where conventional modalities including chemotherapy, radiotherapy, and immune checkpoint blockade often fail to achieve durable responses. Oncolytic adenoviruses (OAds) have emerged as tumor-selective and immunogenic platforms capable of inducing direct oncolytic and systemic antitumor immunity. However, their clinical efficacy is frequently constrained by intrinsic tumor resistance mechanisms, including impaired viral entry, antiviral immune responses, and immunologically "cold" tumor microenvironments. Epigenetic modulation represents a promising strategy to overcome these barriers by reprogramming chromatin accessibility, restoring antigen presentation, and enhancing viral permissiveness. This review explores the mechanistic and translational rationale for integrating OAds with epigenetic therapies, highlighting preclinical and clinical evidence supporting synergistic interactions. We further discuss the implications of this combinatorial approach for precision oncology and its potential to redefine therapeutic paradigms in resistant malignancies.
科研通智能强力驱动
Strongly Powered by AbleSci AI